Products & Services · Total Revenues

Opdualag — Total Revenues

Bristol-Myers Squibb Opdualag — Total Revenues increased by 5.3% to $299.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 28.3%, from $233.00M to $299.00M. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2020
Last reportedQ3 2025
Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market adoption and successful clinical positioning of the drug, while a decrease may signal increased competition or loss of market share in the immuno-oncology space.

Detailed definition

This metric represents the total global net sales generated from the commercialization of Opdualag, a fixed-dose combina...

Peer comparison

Comparable to revenue metrics for specific high-growth specialty pharmaceutical products or blockbusters in the oncology portfolios of peer biopharmaceutical companies.

Metric ID: bmy_segment_opdualag_total_revenues

Historical Data

18 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$0.00$0.00$0.00$6.00M$58.00M$84.00M$104.00M$117.00M$154.00M$166.00M$190.00M$206.00M$235.00M$233.00M$254.00M$252.00M$284.00M$299.00M
QoQ Change+866.7%+44.8%+23.8%+12.5%+31.6%+7.8%+14.5%+8.4%+14.1%-0.9%+9.0%-0.8%+12.7%+5.3%
YoY Change>999%+165.5%+97.6%+82.7%+76.1%+52.6%+40.4%+33.7%+22.3%+20.9%+28.3%
Range$0.00$299.00M
Avg YoY Growth+224.5%
Median YoY Growth+52.6%
Current Streak2 quarters growth

Frequently Asked Questions

What is Bristol-Myers Squibb's opdualag — total revenues?
Bristol-Myers Squibb (BMY) reported opdualag — total revenues of $299.00M in Q3 2025.
How has Bristol-Myers Squibb's opdualag — total revenues changed year-over-year?
Bristol-Myers Squibb's opdualag — total revenues increased by 28.3% year-over-year, from $233.00M to $299.00M.
What does opdualag — total revenues mean?
The total revenue generated from sales of the oncology drug Opdualag.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.